INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Calumet, Inc.

Calumet’s Q2/2026 update highlighted significant EBITDA pressure—Performance Brands adjusted EBITDA fell $6.2M y/y (including a ~$7M LIFO headwind) and Montana Renewables forewent ~$40M of margin due to downtime, while ramp-up of SAF production was deferred to target an additional ~$50M EBITDA at CMR. On the news, CLMT shares fell $2.40 (−5.73%) to close at $39.48. Separately, Pomerantz LLP opened an investigation into potential securities fraud/unlawful business practices, adding a legal overhang despite the operational explanation of the results.

Analysis

The market should treat this less as a one-quarter miss and more as a reset of CLMT’s equity story. The stock was implicitly paying for a renewable-fuels option embedded in a cyclical refinery; repeated slippage turns that option into a capital-allocation burden and supports a lower multiple versus simpler cash converters like DINO and DK. In the near term, the main beneficiary is not a peer but short sellers and vol sellers; the second-order losers are any suppliers or counterparties tied to the SAF buildout, because delayed ramp means delayed volumes and less certainty on offtake timing.

The litigation angle matters because it can elevate the cost of capital before it creates any cash liability. Over the next 1-3 months, the key issue is whether management can show stable operations and a fixed reconfiguration path; if not, the thesis shifts from “temporary timing noise” to “execution plus financing risk,” which can pressure covenant flexibility and lender behavior. The tail risk is another disclosure review or guidance reset that forces the market to price in governance discount rather than just EBITDA volatility.

Contrarian view: the selloff may be somewhat overdone if the deferment truly preserves economics at the conventional refinery and avoids destroying margin during an outage/turnaround window. If the next two prints show normalization, the stock can recover on de-risking alone because the market has already discounted a lot of bad news. What would falsify the bearish read is clear follow-through on SAF ramp, no further EBITDA downgrades, and no incremental legal/regulatory escalation.

Key Decisions for Investors

• Short CLMT on strength over the next 1-3 weeks; use the next earnings/catalyst window as the timing anchor. Risk/reward is attractive if the market continues to re-rate the stock from a growth-story multiple toward a pure-refining multiple. Cover if management reaffirms the SAF timeline and next quarter shows no further operational drag.
• Pair long DINO or DK vs short CLMT to isolate idiosyncratic execution/legal risk from broader refining exposure. This is cleaner than a naked short if crack spreads weaken and the whole group sells off.
• If options liquidity is usable, express downside with a 2-4 month put spread around the current price rather than outright puts; this limits theta bleed if the investigation headline fades. Best entry is after any relief bounce, not on the first down day.
• Set a watch item on borrowing terms and any covenant language in the next filing; if refinancing spreads widen or the company needs to de-emphasize SAF capex again, add to the short. That would be the clearest sign the issue has shifted from optics to balance-sheet risk.